Received 30 December 1998/Returned for modification 22 February
1999/Accepted 26 April 1999
Simian foamy viruses (SFVs) are highly prevalent in a variety of
nonhuman primate species ranging from prosimians to apes. SFVs possess
a broad host range, and human infections can occur by cross-species
transfer (W. Heneine et al., Nat. Med. 4:403-407, 1998). Retrovirus
screening of potential sources of infection, such as laboratory
research animals and simian-derived biological products, could minimize
human exposure to SFVs by reducing the risk of potential retrovirus
infection in humans. We describe a variety of sensitive assays for SFV
isolation and detection which were developed with a prototype strain of
SFV serotype 2. The Mus dunni cell line (M. R. Lander
and S. K. Chattopadhyay, J. Virol. 52:695-698, 1984) was
found to be highly sensitive for SFV production on the basis of various
general and specific retrovirus detection assays such as reverse
transcriptase assay, transmission electron microscopy,
immunofluorescence assay, and Western blotting. A highly sensitive PCR
assay was developed on the basis of the sequences in primary SFV
isolates obtained from pig-tailed macaques (Macaca
nemestrina) and rhesus macaques (Macaca mulatta).
Analysis of naturally occurring SFV infection in macaques indicated
that analysis by a combination of assays, including both highly
sensitive, specific assays and less sensitive, broadly reactive assays,
is important for evaluation of retrovirus infection.
 |
INTRODUCTION |
Foamy viruses (FVs) occur in several
animal species including nonhuman primates (2, 21, 30);
however, there is no direct evidence that FVs are indigenous to humans
(3, 17, 40). Simian FVs (SFVs) possess a broad cell tropism
(20, 21, 29, 46), tissue tropism (1, 13, 15, 21, 22,
33, 34, 43, 45), and species tropism (2, 19, 21, 23).
In fact, cross-species infection of humans has been reported in
handlers of SFV-infected primates (10, 19, 21, 32, 40, 41). In one case SFV was isolated from an infected individual 20 years postexposure (41). In vitro studies have also shown that
SFVs can persist in a latent state (6, 11) and can be
reactivated to produce infectious virus (39). Although there
is no pathogenesis directly associated with SFVs (47), the
long-term consequences of SFV infection in humans may not yet be known.
Various animal models demonstrate that activation and increased
replication of retroviruses can result in acute or slow diseases
(44). Therefore, the long-term presence of a latent,
potentially inducible, infectious retrovirus in humans can raise some
public health safety concerns.
To minimize the risk of cross-species infection of humans with SFVs,
sensitive detection assays can be used to identify FV-infected animals
and to analyze simian-derived biological products for SFV
contamination. This is consistent with the current testing strategy
outlined for retrovirus testing of cell substrates for live, attenuated
viral vaccines (25). Extensive and rigorous retrovirus
testing is particularly important in the case of xenotransplantation since the recipients of animal tissues or organs would be
immunosuppressed and thus potentially more susceptible to virus
infections. In this paper we describe a variety of sensitive detection
assays that may be used to investigate SFV infections in animals and humans and to analyze monkey-derived biological products for retrovirus contamination.
 |
MATERIALS AND METHODS |
Cells and viruses.
The Mus dunni cell line (wild
mouse fibroblast ATCC CRL-2017 [28]) was kindly
provided by Janet Hartley (National Institute of Allergy and Infectious
Diseases, National Institutes of Health). The following cell lines were
obtained from the American Type Culture Collection (ATCC; Rockville,
Md.): Vero (African green monkey kidney; ATCC CCL-81), Cf2Th (canine
thymus; ATCC CRL-1430), A204 (human rhabdomyosarcoma; ATCC HTB-82), and
A549 (human lung carcinoma; ATCC CCL-185) cells. HeLa (human
epithelioid carcinoma) cells were obtained from the AIDS Research and
Reference Reagent Program (Richard Axel, Division of AIDS, National
Institute of Allergy and Infectious Diseases, National Institutes of
Health). Primary chicken embryo fibroblasts (CEFs) were prepared from
10-day-old embryos (SPAFAS, Inc., Preston, Conn.). Cells were
maintained in a 75-cm2 flask in 13 ml of Dulbecco's
modified Eagle medium supplemented with 10% fetal bovine serum (heat
inactivated; Gibco, Grand Island, N.Y.), 2 mM L-glutamine,
250 U of penicillin per ml, and 250 µg of streptomycin per ml
(designated complete medium).
The M. dunni, Cf2Th, Vero, and HeLa cell lines were infected
in parallel at 75% confluence with 0.1 ml (281 50% tissue culture infective doses [TCID50s]) of freshly reconstituted SFV
serotype 2 (SFV-2; (102.75 TCID50s per 0.2 ml
in MRC-5 cells; 22 days; ATCC catalog no. VR 277, FV-34, lot 4D,
91-10). The infection was set up in duplicate in complete medium
containing Polybrene (4 µg per ml); one uninfected flask was set up
as a negative control for each of the cell lines. The cells were split
when they reached confluence (every 3 to 4 days) or were fed fresh
medium. Filtered supernatants (0.45-µm-pore-size test tube top filter
units; Corning, Cambridge, Mass.) were collected, aliquoted, and saved
at
80°C for reverse transcriptase (RT) analysis. The cultures were
regularly monitored for cytopathic effect (CPE). CPEs that ranged from
1+ to 4+, which were equivalent to about 25 to 95% cell death, were
noted. The cultures were propagated until extensive cell lysis (4+ CPE
[
90%]) occurred or until there was extensive accumulation of
floating dead cells in the supernatant.
A204, A549, and CEF cells were infected with 0.2 ml (103.35
TCID50s) of a new lot of SFV-2 which contained a higher
virus titer (103.5 TCID50s per 0.5 ml in A72
cells; 7 days; ATCC; lot 5W, 95-12). The infection and propagation of
the cells were done under the conditions described above. The cultures
were monitored for CPE, and filtered supernatants were collected for RT analysis.
To assess the contribution of cellular polymerases to the RT activity
in samples that were collected at times of extensive cell lysis,
confluent uninfected cultures were lysed by four freeze-thaw cycles of
the flask containing 13 ml of complete medium, and the samples were
subsequently handled similarly to the infected cultures.
The sensitivity of SFV detection in infected macaques was determined by
cocultivation of monkey peripheral blood mononuclear cells (PBMCs) with
M. dunni cells. The animals were maintained in accordance
with the Guide for the Care and Use of Laboratory Animals
(31) under a protocol approved by the Center for Biologics Evaluation (CBER) Animal Care and Use Committee. A pig-tailed macaque
(Macaca nemestrina), designated animal Mn97, had
previously been identified as seropositive on the basis of
immunofluorescence assay (IFA; Microbiological Associates Inc.,
Rockville, Md.). PBMCs from Mn97 were prepared by the
Ficoll-Hypaque procedure from heparinized blood, aliquoted, and
cryopreserved. Unstimulated PBMCs (5 × 106) were
cocultured with 2 × 106 trypsinized M. dunni cells in 20 ml of complete Dulbecco's modified Eagle medium
containing Polybrene (4 µg/ml). The medium was changed on the next
day and was replaced with medium without Polybrene. The cultures were
further propagated and monitored for CPE, and filtered supernatants
were collected as described above until extensive cell lysis occurred.
Generally, at each medium change, prior to filtration, the PBMCs in the
supernatant were pelleted by centrifugation at 1,500 rpm for 10 min
(Beckman GS-6KR centrifuge with a GH-3.8 horizontal rotor; Beckman,
Columbia, Md.) and added back to the M. dunni cells. To
determine the lowest number of PBMCs from Mn97 from which
virus could be recovered, cells were serially diluted and cocultured
with 7.5 × 105 M. dunni cells initially in
a 25-cm2 flask in 4 ml of complete medium in the presence
of Polybrene. The cells were subsequently transferred to a
75-cm2 flask. Two 10-fold dilution series of PBMCs
(1.8 × 106 to 0.018 cells and 4.5 × 105 to 0.045 cells) were tested in independent
cocultivation experiments. The cultures were handled as described
above, and supernatants were collected until termination of the
cultures due to extensive cell lysis.
RT assay.
RT assay was performed with 10 µl of sample and
50 µl of RT cocktail for 2 h in a 37°C water bath. The RT
cocktail consisted of 50 mM Tris-HCl (pH 8.3), 60 mM NaCl, 20 mM
dithiothreitol, 0.05% Nonidet P-40, 0.6 mM MnCl2, 10 µg
of poly(A) per ml, and 5 µg of pdT12-18 per ml. One microliter of
[
-32P]dTTP (0.5 µCi; >400 Ci/mmol; Amersham Corp.,
Arlington Heights, Ill.) was added per ml of cocktail just prior to
use. Five microliters of the reaction mixture was spotted in duplicate
onto DE81 filter paper (Whatman) and air dried. Unbound 32P
was removed by four 5-min washes in 2× SSC (1× SSC is 0.15 M NaCl
plus 0.015 M sodium citrate) and two 1-min washes in 95% ethanol. The
filters were dried and exposed to X-ray film overnight at
80°C.
Subsequently, the radioactivity in the spots was counted in a liquid
scintillation counter. All the samples from the different cultures were
tested in the same RT experiment to avoid any differences in the
results due to assay variability. Two independent RT experiments, each
spotted in duplicate, were performed with each infected cell culture
and the uninfected control flask. The results (means ± standard
deviations [SDs]) of the two experiments were calculated.
Transmission electron microscopy (TEM).
Uninfected and
SFV-2-infected cells (with CPEs ranging from about 1+ to 3+) were
pelleted and fixed for 2 to 3 h with 2% glutaraldehyde-2% paraformaldehyde in 0.1 M sodium cacodylate buffer (pH 7.3). The samples were stored in phosphate-buffered saline (PBS) with 4% sucrose
at 4°C. The cells were subsequently postfixed with 2% osmium
tetroxide, dehydrated with graded alcohols, and embedded in epoxy
resin. Thin sections were stained with uranyl acetate and lead citrate
and were examined for virus particles with a Zeiss EM 912 Omega
electron microscope.
IFA.
Infected cells were plated onto coverslips. At the
appearance of a 1+ to 2+ CPE, the cells were fixed with ice-cold
acetone-methanol (1:1). Fixed cells were incubated in a humidified
chamber on a rocker for 30 min at 37°C with a 1:40 dilution (in PBS
[pH 7.4]) of plasma from animal Mn97. The cells were then
incubated with fluorescein isothiocyanate-conjugated anti-monkey serum
(1:160 dilution; Sigma Chemical Co., St. Louis, Mo.) and observed for staining with a ×60 objective in an Olympus fluorescence microscope. Uninfected cells (negative controls) were treated in parallel.
Western blot analysis.
Uninfected and SFV-2-infected cells
(at a CPE of about 2+) were harvested by scraping and washed with
Dulbecco's PBS (pH 7.4). The cell lysates were prepared in buffer
consisting of 50 mM Tris-HCl (pH 8.0), 5 mM EDTA, 100 mM sodium
chloride, 0.2% deoxycholate, and 0.5%
3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate (CHAPS;
Behring Diagnostics, La Jolla, Calif.). The protein concentration was
determined with a protein assay dye (Bio-Rad, Hercules, Calif.). Five
micrograms of protein was heat denatured and analyzed on an 8 to 16%
Tris-glycine-polyacrylamide gel (Novex, San Diego, Calif.), the gel was
run for 3 h at 90 V in 1× Tris-glycine running buffer (24.8 mM
Tris, 192 mM glycine, 0.1% sodium dodecyl sulfate), and the protein
was transferred to a nitrocellulose filter in 24.8 mM Tris-192 mM
glycine-20% methanol. After protein transfer onto the nitrocellulose
filter at 30 V for 1.5 h, the filter was blocked overnight in PBS
(pH 7.3)-0.05% Tween-5% nonfat dried milk (designated PBST+5%) at
room temperature and was then incubated with a 1:100 dilution of plasma
from animal Mn97. The filter was incubated for 2 h at
room temperature and then overnight at 4°C on a rocker. The filter
was washed four times in PBST+5% and was then incubated for 2 h
at room temperature with a 1:500 dilution of horseradish
peroxidase-conjugated goat anti-monkey immunoglobulin G (Cappel
Research Products, Durham, N.C.) in PBST+5%. The filter was then
washed (whole molecule; six times for 5 min each in PBS-Tween, and the
protein bands were visualized by chemiluminescence with the Supersignal
CL-HRP-substrate system (Pierce, Rockford, Ill.). The substrate was
added to the filter generally for 3 to 5 min, and the filter was then
blotted with paper to remove excess substrate and then exposed to
BioMax MR film (Kodak, Rochester, N.Y.) for various times ranging from
5 s to 2 min.
PCR assay.
DNA was prepared from monkey PBMCs and from
M. dunni cells infected with prototype strains of SFV-1 and
SFV-2 (SFV-1 strain FV-21 [catalog no. VR-276; ATCC]; SFV-2 strain
FV-34 [catalog no. VR-277; ATCC]). Set A primers were synthesized on
the basis of the published sequence of SFV-1 (27, 29). The
outer primer pair of set A consisted of forward primer 1 (5'-GGAATGCAGTGGGTATAGAG-3') and reverse primer 2 (5'-CCTGATATCAATTGTGGTGG-3'), and the inner primer pair
consisted of forward primer 3 (5'-CAGTGAATTCCAGAATCTCTTC-3') and reverse primer 4 (5'-TATCCTTAGGAACTAACACCT-3').
Set B primers were synthesized on the basis of the highly
conserved sequences identified in the long terminal repeats (LTRs) of
SFVs, which had been isolated with primer set A from naturally infected
rhesus and pig-tailed macaques (42). The outer primer pair
of set B consisted of forward primer 3 (5'-CAGTGAATTCCAGAATCTCTTC-3') and reverse primer 5 (5'-CACTTATCCCACTAGATGGTTC-3'), and the inner primer pair
consisted of forward primer 6 (5'-CCAGAATCTCTTCATACTAACTA-3') and reverse primer 7 (5'-GATGGTTCCCTAAGCAAGGC-3'). The
PCR conditions for both the outer and inner primer pairs of primer sets
A and B were the same. The reaction was carried out with a 100-µl
reaction mixture with 5 U of Taq DNA polymerase according to
the manufacturer's instructions (Boehringer Mannheim, Indianapolis,
Ind.). For the first amplification, 35 cycles were done at 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min. Ten microliters of the
reaction mixture was reamplified under the same PCR conditions. The
sensitivity of PCR detection by the outer primer pair of set B was
determined by using a panel of DNAs which were created by spiking
different copy numbers of cloned SFV-2 LTR DNA in 105 cell
equivalents of M. dunni DNA. The SFV-2 LTR fragment was amplified with the outer primer pair of set A and was cloned into vector DNA. PCR-amplified DNA products were analyzed on agarose gels
and were visualized by staining with ethidium bromide. PCR primers,
which were used to detect the human
-actin gene (Clontech, Palo
Alto, Calif.) as a control for the presence of DNA in the sample,
amplified an 838-bp DNA fragment. The PCR mixture without DNA was used
as the negative control.
 |
RESULTS |
SFV replication in different cell lines.
Both SFV-1 and SFV-2
replicated efficiently in M. dunni cells. The kinetics of
SFV-2 replication were analyzed in the Cf2Th, M. dunni,
HeLa, and Vero cell lines, and the results are shown in Fig.
1. In general, RT activity increased over
time postinfection (p.i.) and peaked when the maximum CPE (4+) was
reached, at which time the culture was terminated. The highest RT
activity was seen in M. dunni cells, in which a CPE was
first noted on day 7 p.i.; on day 8 the cells reached a CPE of 2+
and progressed rapidly to a CPE of 4+ at the end of passage 3 (p3), on
day 12. The peak RT activity at the time of termination of the culture
was about 16-fold above that at the initial time point. Although SFV
was most abundantly produced in M. dunni cells, Cf2Th cells
were the most sensitive to the CPE, which was first seen at day 4 and
which progressed rapidly, with the culture being terminated due to
extensive cell death at the end of p2 on day 7. However, the RT
activity at this time was about fivefold lower than the peak RT
activity in M. dunni cells. In the case of HeLa cells, the
peak RT activity was similar to that seen in Cf2Th cells; however, the
kinetics of virus replication and CPE progression were delayed. In the HeLa cells, a CPE was first noted on day 16, which was at the end of
p4, and progressed until day 21, when the culture was terminated (end
of p6). In this case, the peak RT level reached at the time of
termination of the culture was about fourfold above the background level. SFV-2 replication was very slow in Vero cells: a CPE was first
noted at p5 on day 13 and the CPE progressed slowly to 2+ on day 23. The duplicate cultures in the two infected flasks were terminated on
day 29 and day 33, respectively, at the end of p10 when a 3.5+ CPE was
seen. Low-level RT activity was detected in the infected Vero cell
cultures at the termination of the cultures. Although this level of RT
activity was above that for the negative control culture supernatant,
it was not clear whether the RT activity was associated with virus or
cellular enzymes which were released in the supernatant due to the cell
lysis caused by SFV. Thus, the RT activity in the supernatants of
infected Vero cells was compared with that in an uninfected cell lysate
(data not shown). The results indicated a low level RT activity in both
samples. Therefore, SFV infection of Vero cells was confirmed by other detection assays (described below).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 1.
Kinetics of SFV-2 virus replication in different cell
lines. SFV-2 virus replication was monitored at various time points
p.i. of M. dunni cells, Cf2Th cells, HeLa cells, and Vero
cells. Filtered supernatant was assayed in two independent RT assays.
Each sample was spotted in duplicate. The means ± SDs (error
bars) for each infected culture ( , ) and the uninoculated control
cells ( ) are shown. The progression of cytopathogenicity is
indicated, ranging from no CPE ( ) to about 90% CPE (4+).
|
|
To further assess the replication of SFV in human cells, A204 and A549
cell lines were infected with SFV by using an eightfold greater
concentration of infectious virus than that used in the studies
described above. The results, shown in Fig.
2, indicate low levels of RT activity in
both cell lines on day 14 p.i. To investigate the broad host range
of SFV-2, CEF cells were infected and the kinetics of replication of
SFV were analyzed (Fig. 2). Although the cells were highly sensitive to
the CPE and extensive cell lysis was seen on day 11 p.i., the
level of RT activity was low. Infection of chicken cells with FVs has
previously been shown for SFV-1 (38) and baboon FV serotype
10 (36).

View larger version (10K):
[in this window]
[in a new window]
|
FIG. 2.
Kinetics of SFV-2 replication in human and chicken
cells. A204, A549, and CEF cells were inoculated with SFV-2 at an
eightfold greater concentration than that used in the experiment
described in the legend to Fig. 1. RT activity was detected in filtered
supernatants of SFV-2 infected cells ( ). Parallel uninfected cells
were the negative control ( ). The CPE at various time points is
indicated as negative ( ) or positive (+). The infection was done in a
single experiment; the RT data are the means ± SDs (error bars)
for two independent RT assays in which each sample was spotted in
duplicate.
|
|
IFA analysis.
SFV-2 infection in the different cell lines was
further analyzed by IFA with plasma from animal Mn97.
Intense staining and multinucleated syncytia were seen in the infected
cells but not in the uninfected cells (Fig.
3), indicating high levels of viral protein expression. The intensity and cellular localization of the
stained signal varied in the different infected cell lines: intense
granular cytoplasmic and perinuclear staining was seen in M. dunni cells (Fig. 3a) and HeLa cells (Fig. 3e), while little staining was seen in the nucleus. In Vero cells (Fig. 3g) cytoplasmic and nuclear staining was seen; however, the staining was mostly perinuclear. In the case of the Cf2Th cells (Fig. 3c), intense nuclear
staining and diffuse cytoplasmic staining were seen. The differences in
the cellular locations of the signals may be due to asynchronous
infection of the cells in the culture. Differential expression of viral
proteins in the cytoplasm versus the nucleus has previously been shown
to be dependent on the time p.i. in the case of SFV-1 (16)
and human foamy virus (37).

View larger version (93K):
[in this window]
[in a new window]
|
FIG. 3.
Immunofluorescence of SFV-2 infected cells. IFAs of
uninfected and virus-infected M. dunni (a and b,
respectively), Cf2Th (c and d, respectively), HeLa (e and f,
respectively) and Vero (g and h, respectively) cells were done with
plasma from animal Mn97 as described in Materials and
Methods. Multinucleated syncytia as well as singly stained cells were
seen in virus-infected cells, whereas no signal was seen in the
uninfected cultures. Intense cytoplasmic and perinuclear staining was
seen in infected M. dunni, HeLa, and Vero cells (a, e, and
g, respectively). In Cf2Th cells, intense nuclear and diffuse
cytoplasmic staining were seen (c).
|
|
TEM analysis.
SFV-2 infection of the different cell lines was
further confirmed by TEM. Analysis of normal and infected cells
indicated particles characteristic of SFV in the infected cells;
however, the amount and location of virus produced varied in the
different cell lines. In addition, analysis of cells at different
stages of the CPE (1+ to 3+) indicated an increase in the number of
virus particles with progression of the CPE. In general, the levels of
extracellular virus production directly correlated with the RT
activity. Abundant intracellular and extracellular virus was seen in
M. dunni cells (Fig. 4a to c).
In the case of the M. dunni cells, large numbers of virus
cores were associated with parallel arrays of rough endoplasmic
reticulum (ER) membranes surrounding the nucleus (Fig. 4a). In some
cases very enlarged structures consisting of extensively developed
membranes and viral cores were seen adjacent to the nucleus (Fig. 4b).
Numerous SFV particles with a characteristic spiked envelope were seen
budding from the plasma membrane and extracellularly (Fig. 4c). In
contrast to M. dunni, few infected Vero cells were observed,
and these had very few intracellular or extracellular particles (Fig.
4d). In the case of SFV-infected Cf2Th cells, little budding occurred at the plasma membrane, and therefore, few extracellular particles were
seen (Fig. 4e). However, in these cells there was abundant intracellular accumulation of enveloped virus in dilated ER membranes (Fig. 4f). SFV-infected HeLa cells produced few extracellular particles, like the Cf2Th and Vero cells; however, they were different from the other infected cells, including M. dunni, in that
they were highly vacuolated and contained enveloped particles (Fig. 4g
and h).

View larger version (169K):
[in this window]
[in a new window]
|
FIG. 4.
TEM of SFV-2-infected cells. SFV particles were seen
intracellularly and budding from the plasma membrane. Infected M. dunni cells (a to c) had viral cores associated with
extensively duplicated ER membranes, which were adjacent to the nucleus
(a and b). Abundant mature particles were seen budding
extracellularly from the plasma membrane (c). Infected Vero cells
had few mature particles, which bud from the plasma membranes (d). In
the case of infected Cf2Th cells (e and f) apoptotic cells were seen
with few extracellular particles (e) and abundant accumulation of
enveloped particles intracytoplasmically in dilated cisternae of the ER
(f). In infected HeLa cells, enveloped particles were seen in the
vacuolated cytoplasm of apoptotic cells (g and h). Few particles were
seen to be budding from the plasma membrane. N, nucleus; the boxed
region in panel g is magnified in panel h to show virus particles.
Bars, 0.5 µm in panels a to f and h and 1 µm in panel g.
|
|
SFV-2 infection of HeLa cells and Cf2Th cells resulted in apoptosis.
Cellular changes indicative of apoptosis were seen, including chromatin
condensation and nuclear segmentation (Fig. 4f and 4g) (24).
These results indicate that SFV can have two mechanisms of cell death:
lysis and apoptosis. The difference between the nucleus of an apoptotic
cell and that of a nonapoptotic cell can be seen by comparing the
chromatin distributions in the nuclear regions (designated N) of Cf2Th
and HeLa cells (Fig. 4f and g, respectively) with that in the nuclear
region of M. dunni cells (Fig. 4a).
Western blot analysis.
To analyze the efficiency of virus
production in the different cell lines, similar amounts of protein
lysates from infected and uninfected cells were analyzed by Western
blotting (Fig. 5). Numerous
virus-specific proteins were highly expressed in the SFV-2-infected
M. dunni cells (Fig. 5A, lane 1). Some of the proteins were
comparable in size to those previously reported for the SFV-1 and SFV-3
Gag, Pol, and Env proteins, e.g., 134 kDa for the Pol precursor
(35), 77 kDa for the RT (80 kDa) (8), 117 kDa for the Env precursor (27), 71 kDa for the Env glycoprotein (70 kDa) (7, 9) and 70 kDa for the Gag precursor (69 kDa)
(27). Small amounts of the gag-encoded major core
protein (30 kDa) (8, 9) were detected, indicating
inefficient processing of the precursor proteins. A novel large protein
(156 kDa) was detected in SFV-infected M. dunni cells.
However, specific SFV reagents were not available to characterize the
different proteins. Proteins of similar sizes were detected in Cf2Th,
Vero, and HeLa cells (Fig. 5A, lanes 3, 5, and 7, respectively). Some
of the bands were seen only when larger amounts of the lysates were
analyzed (data not shown). In general, protein expression in the
different cell lines correlated with the levels of virus production
seen by the other detection assays (i.e., M. dunni > Cf2Th > HeLa > Vero); however, the number and amount of
proteins detected in the different cell lines depended upon the stage
of infection at the time of preparation of the cell lysate. This was
evidenced by the increased expression of the 71- and 65-kDa proteins in Cf2Th cells when the cells were harvested when the CPE was 3+ (Fig. 5B,
lane 2) compared with that when the cells were harvested when the CPE
was 2+ (Fig. 5A, lane 3). Western blot analysis of virus concentrated
from filtered supernatant of SFV-2-infected M. dunni cells
by pelleting through a sucrose cushion produced a protein profile
identical to that for the infected cell lysate, thus indicating the
presence of both extracellular and intracellular particles in the virus
preparation. The small amount of the 30-kDa protein, which corresponds
to the major viral capsid protein, in the virus preparation indicated a
low yield of mature virions (data not shown).

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 5.
Western blot analysis of SFV-2-infected cells. Five
micrograms of protein from lysates of the following SFV-2-infected
cells (at a CPE of 2+) were immunoblotted with SFV-positive monkey
plasma (A): M. dunni (lane 1), Cf2Th (lane 3), Vero (lane
5), and HeLa (lane 7). Uninfected cell lysates were the negative
controls, as follows: M. dunni (lane 2), Cf2Th (lane 4),
HeLa (lane 6), and Vero (lane 8) cells. In addition, Cf2Th cells were
analyzed when the CPE was 3+ (B). Lane 1, uninfected cells; lane 2, infected cells. The sizes of some of the prominently visible SFV-2
proteins in M. dunni are indicated. The molecular masses
were calculated from standard markers (SeeBlue; Novex, San Diego,
Calif.) and are indicated in kilodaltons. The filter shown in panel A
was incubated in substrate for 3 min and remained at room
temperature for about 30 min before autoradiography. It was then
exposed to X-ray film for 1 min. The filter shown in panel B was
incubated in substrate for 10 s and immediately exposed to X-ray
film for 10 s.
|
|
Isolation of SFV from pig-tailed macaque PBMCs by using the
M. dunni cell line.
The efficiency of SFV isolation in
M. dunni cells was further assessed in coculture studies
with PBMCs from animal Mn97. Initial cocultivation studies
with unstimulated PBMCs and M. dunni cells indicated that
SFV could be detected by the CPE at p3 on day 12. This was confirmed by
the presence of RT activity in a sample collected at p4 on day 14. Subsequently, various dilutions of PBMCs from Mn97 were
cocultivated with M. dunni cells to estimate the sensitivity
of isolation of SFV from an infected monkey. The results indicated that
virus could be recovered from at least 4.5 × 105
cells on day 21 at p6 after coculture (Table
1). FVs were not detected with 1.8 × 105 cells at day 25 (p8) or other, lower dilutions,
including 4.5 × 104 cells, which remained negative
even at p11 (39 days). On the basis of these results the sensitivity of
virus detection in M. dunni cells is at least 1 infected
cell in 4.5 × 105 cells at p6.
Development of sensitive PCR primers for detection of SFV in
macaques.
To study natural SFV infection and virus transmission in
macaques, 28 monkeys (16 Macaca nemestrina and 12 Macaca mulatta macaques) were analyzed by the various
detection assays described above (26). SFV infection was
initially determined by screening monkey plasma for viral antibodies by
IFA, and the results were further evaluated by PCR analysis and virus
isolation with monkey PBMCs. The IFA and PCR results for selected
animals are shown in Table 2. Initially,
PCR primer set A was developed on the basis of known SFV-1 sequences
and was used in the analysis. As seen in Table 2, there was a
correlation between the IFA data and the PCR data for four positive and
two negative animals. However, MmG2K and MmJ4G
were positive by IFA and negative by PCR. To address this discordance
in the results, PCR primer set B was developed on the basis of highly
conserved sequences present in the LTRs of viral DNAs of primary SFV
isolates of different macaque species. As shown in Table 2, this set of
primers was able to detect SFV sequences in MmG2K and
MmJ4G, which were negative in tests with primer set A. Thus,
there was a perfect correlation between the IFA and PCR data when the
more sensitive primer set B was used. In addition, primer set B could
also detect SFVs in Macaca nemestrina as well as SFV-1 from
Macaca cyclopsis. Thus, primer set B was found to be broadly
reactive for the detection of SFVs in different macaque species.
The sensitivity of PCR detection was determined by evaluating the
detection of SFV sequences in a background of uninfected cellular DNA
by using SFV-2 as a prototype virus. A 390-bp DNA fragment was
amplified with the outer primer pair of primer set B. The results
indicated detection of 10 viral copies in 105 cell
equivalents of uninfected M. dunni DNA (Fig.
6). The specificity of the primers was
demonstrated by the absence of amplified fragments in DNAs prepared
from uninfected monkey or human PBMCs (data not shown).

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 6.
Detection of SFV by PCR. The sensitivity of PCR
detection with set B outer primer pair was determined by amplification
of M. dunni DNA (105 cell equivalents)
containing different numbers of copies of cloned SFV-2 DNA. The number
of copies of cloned DNA and the size of the PCR-amplified fragment are
indicated. Primers used for detection of the human -actin gene,
which was used as a control for the presence of DNA in each sample,
amplified the fragments of the expected sizes.
|
|
 |
DISCUSSION |
The broad host range and high prevalence of SFVs in nonhuman
primates can result in cross-species transmission of SFVs from infected
animals to humans (10, 21, 32, 39, 41, 45). Although there
is no evidence of SFV-induced disease in animals or humans
(47), the virus can remain in a latent, inducible state in
vitro (6, 11) and persist long term in vivo (41). In fact, Schweizer et al. (41) were successful in isolating infectious SFV, after prolonged coculture, from stimulated PBMCs of an
infected individual who had had a persistent and clinically latent
infection for about 20 years (41). Since retroviruses can
cause acute or slow diseases and since transient immune suppression following FV infection has been shown in rabbits (40), the
presence of an infectious, albeit latent, retrovirus such as SFV in
humans raises concerns regarding public health safety. Therefore, to minimize the potential risk of cross-species transfer of retroviruses to humans, sensitive detection assays should be used to screen potential sources of infection such as nonhuman primates and
simian-derived biological products. In this paper we have described
various assays that may be used to detect SFV in infected animals or
humans and in monkey-derived biological products. We have used some of
the assays to analyze naturally occurring SFV infections in
Macaca mulatta and Macaca nemestrin monkeys. The
results indicated that rigorous testing is necessary for retrovirus
detection, such as use of a combination of selected general and
specific assays for the detection of known as well as novel viruses.
Furthermore, the most sensitive assays which can identify the presence
of low-level or latent retroviruses should be used: for example, assays
that use the M. dunni cell line, which is highly sensitive
for SFV isolation, and the set B PCR primers, which can detect SFVs in different macaque species.
Analysis of different cell lines for susceptibility to SFV-2 infection
identified M. dunni cells as the most sensitive cell line
for virus production. In addition, the comparative infectivity studies
indicated that SFV-2 replicated at low levels in human cells and poorly
in monkey cells compared with the levels of replication in cells
of other species, e.g., mouse and dog cells. The inefficient viral
replication in primate cells may reflect the inability of the virus to
induce pathogenesis in this species. The initial low level of virus
replication could produce immune responses in vivo, such as high levels
of neutralizing antibodies (43), which might result in a
low-level virus burden and chronic infection without clinical symptoms.
The persistence of a retrovirus in the absence of disease induction in
its natural host has also been seen in the case of the simian
immunodeficiency virus (SIV) (4). However, upon
cross-species transfer, SIV can replicate efficiently, resulting in
AIDS in Asian macaques. In general, increased viremia can result
in retrovirus-induced diseases. For example, murine amphotropic,
replication-competent retrovirus was found to be nonpathogenic in
healthy macaques (12) but induced T-cell lymphomas in highly
immunosuppressed animals (14). Furthermore, live, attenuated
SIV that contained deletions in nef, vpr, and negative regulatory element (NRE) regions protected adult monkeys against infection with pathogenic virus (48), whereas the
same virus produced AIDS in infant monkeys (5). Thus, to
fully assess whether SFV may be pathogenic in humans, studies with
animals need to be done to evaluate SFV replication with regard to the host immune status and age as well as the virus dose and route of exposure.
We thank T. Bryan and M. Lundquist for technical assistance, A. Thompson for preparation of the CEF cells, P. Snoy and R. Olsen for
veterinary services, and K. Peden and H. Golding for comments on the manuscript.
| 1.
|
Agrba, V. Z.,
L. V. Kokosa,
G. N. Cuvirov,
D. Bierwolf,
R. Widmaier,
A. Graffi,
B. A. Lapin,
I. A. Sangulia, and M. Rudolph.
1978.
Isolation of foamy virus type II out of haematopoietic cells from baboons with haemagoblastoses and from healthy animals.
Arch. Geschwulstforsch.
48:97-111[Medline].
|
| 2.
|
Aguzzi, A.
1993.
The foamy virus family: molecular biology, epidemiology and neuropathology.
Biochim. Biophys. Acta
1155:1-24[Medline].
|
| 3.
|
Ali, M.,
G. P. Taylor,
R. J. Pitman,
D. Parker,
A. Rethwilm,
R. Cheingsong-Popov,
J. N. Weber,
P. D. Bieniasz,
J. Bradley, and M. O. McClure.
1996.
No evidence of antibody to human foamy virus in widespread human populations.
AIDS Res. Hum. Retroviruses
12:1473-1483[Medline].
|
| 4.
|
Allan, J. S.
1991.
Pathogenic properties of simian immunodeficiency viruses in nonhuman primates, p. 191-206.
In
W. Koff, et al. (ed.), Annual review of AIDS research, vol. 1. Marcel Dekker, Inc., New York, N.Y.
|
| 5.
|
Baba, T. W.,
Y. S. Jeong,
D. Pennick,
R. Bronson,
M. F. Greene, and R. M. Ruprecht.
1995.
Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques.
Science
267:1820-1825[Abstract/Free Full Text].
|
| 6.
|
Baker, E. F.
1989.
Latent simian foamy virus.
S. Afr. Med. J.
76:451-452[Medline].
|
| 7.
|
Benzair, A. B.,
A. Rhodes-Feuillette,
J. Lasneret,
R. Emanoil-Ravier, and J. Peries.
1985.
Purification and characterization of the major envelope glycoprotein of simian foamy virus type I.
J. Gen. Virol.
66:1449-1455[Abstract/Free Full Text].
|
| 8.
|
Benzair, A. B.,
A. Rhodes-Feuillette,
J. Lasneret,
R. Emanoil-Ravier, and J. Peries.
1986.
Purification and characterization of simian foamy virus type I structural core polypeptides.
Arch. Virol.
87:87-96[Medline].
|
| 9.
|
Cavalieri, F.,
A. Rhodes-Feuillette,
A. B. Benzair,
R. Emanoil-Ravicovitch, and J. Peries.
1981.
Biochemical characterization of simian foamy virus type I.
Arch. Virol.
68:197-202[Medline].
|
| 10.
|
Centers for Disease Control and Prevention.
1997.
Nonhuman primate spumavirus infections among persons with occupational exposure in United States, 1996.
Morbid. Mortal. Weekly Rep.
46:129-131[Medline].
|
| 11.
|
Clarke, J. K.,
J. Samuels,
E. Dermott, and F. W. Gay.
1970.
Carrier cultures of simian foamy virus.
J. Virol.
5:624-631[Abstract/Free Full Text].
|
| 12.
|
Cornetta, K.,
R. A. Morgan,
A. Gillio,
S. Sturm,
L. Baltrucki,
R. O'Reilly, and W. F. Anderson.
1991.
No retroviremia or pathology in long-term follow-up of monkeys exposed to a murine amphotropic retrovirus.
Hum. Gene Ther.
2:215-219[Medline].
|
| 13.
|
DiGiacomo, R. F.,
H. J. Hooks,
M. P. Sulima,
C. J. Gibbs, and C. Gajudesek.
1977.
Pelvic endometriosis and simian foamy virus infection in a pigtailed macaque.
J. Am. Vet. Med. Assoc.
171:859-861[Medline].
|
| 14.
|
Donahue, R. E.,
S. W. Kessler,
D. Bodine,
K. McDonagh,
C. Dunbar,
S. Goodman,
B. Agricola,
E. Byrne,
M. Raffeld,
R. Moen,
R. J. Bacher,
K. M. Zsebo, and A. W. Nienhuis.
1992.
Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer.
J. Exp. Med.
176:1125-1135[Abstract/Free Full Text].
|
| 15.
|
Feldman, M. D.,
N. R. Dunnick,
D. W. Barry, and P. D. Parkman.
1975.
Isolation of foamy virus from rhesus, African green and cynomolgus monkey leukocytes.
J. Med. Primatol.
4:287-295[Medline].
|
| 16.
|
Fleming, W. A., and J. K. Clarke.
1970.
Fluorescence assay of foamy virus.
J. Gen. Virol.
6:277-284[Abstract/Free Full Text].
|
| 17.
|
Goepfert, P. A.,
G. D. Ritter, Jr.,
X. Peng,
A. A. Gbakima,
Y. Zhang, and M. M. Mulligan.
1996.
Analysis of West African hunters for foamy virus infections.
AIDS Res. Hum. Retroviruses
12:1725-1730[Medline].
|
| 18.
|
Heneine, W.,
W. M. Switzer,
P. Sandstrom,
J. Brown,
S. Vedapuri,
C. A. Schable,
A. S. Khan,
N. W. Lerche,
M. Schweizer,
D. Neumann-Haefelin,
L. E. Chapman, and T. M. Folks.
1998.
Identification of a human population infected with simian foamy viruses.
Nat. Med.
4:403-407[Medline].
|
| 19.
|
Hooks, J. J., and B. Detrick-Hooks.
1979.
Simian foamy virus-induced immunosuppression in rabbits.
J. Gen. Virol.
44:383-390[Abstract/Free Full Text].
|
| 20.
|
Hooks, J. J., and B. Detrick-Hooks.
1981.
Spumavirinae: foamy virus group infections. Comparative aspects and diagnosis, p. 599-618.
In
E. Kurstak, and C. Kurstak (ed.), Comparative diagnosis of viral disease. Academic Press, Inc., New York, N.Y.
|
| 21.
|
Hooks, J. J., and J. Gibbs, Jr.
1975.
The foamy viruses.
Bacteriol. Rev.
39:169-185[Free Full Text].
|
| 22.
|
Johnston, P. B.
1961.
A second immunologic type of simian foamy virus: monkey throat infections and unmasking by both types.
J. Infect. Dis.
109:1-9[Medline].
|
| 23.
|
Johnston, P. B.
1971.
Taxonomic features of seven serotypes of simian and ape foamy viruses.
Infect. Immun.
3:793-799[Abstract/Free Full Text].
|
| 24.
|
Kerr, J. F. R., and B. V. Harmon.
1991.
Definition and incidence of apoptosis: a historical perspective, p. 5-50.
In
L. D. Tomei, and F. O. Cope (ed.), Apoptosis: the molecular basis of cell death. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 25.
|
Khan, A. S.
1996.
Retrovirus screening of vaccine cell substrates.
Dev. Biol. Stand.
88:155-160.
|
| 26.
| Khan, A. S., et al. Unpublished data.
|
| 27.
|
Kupiec, J.-J.,
A. Kay,
M. Hayat,
R. Ravier,
J. Peries, and F. Galibert.
1991.
Sequence analysis of the simian foamy virus type 1 genome.
Gene
101:185-194[Medline].
|
| 28.
|
Lander, M. R., and S. K. Chattopadhyay.
1984.
A Mus dunni cell line that lacks sequences closely related to endogenous murine leukemia viruses and can be infected by ectropic, amphotropic, xenotropic, and mink cell focus-forming viruses.
J. Virol.
52:695-698[Abstract/Free Full Text].
|
| 29.
|
Mergia, A.,
N. J. Leung, and J. Blackwell.
1996.
Cell tropism of the simian foamy virus type 1 (SFV-1).
J. Med. Primatol.
25:2-7[Medline].
|
| 30.
|
Morris, J. A.,
M. Saglam, and F. M. Bozeman.
1965.
Recovery of a new syncytium virus from a cottontail rabbit.
J. Infect. Dis.
115:495-499[Medline].
|
| 31.
|
National Research Council.
1996.
Guide for the care and use of laboratory animals.
National Academy Press, Washington, D.C.
|
| 32.
|
Neumann-Haefelin, D.,
A. Rethwilm,
G. Bauer,
F. Gudat, and H. zur Hausen.
1983.
Characterization of a foamy virus isolated from Cercopithecus aethiops lymphoblastoid cells.
Med. Microbiol. Immunol.
172:75-86[Medline].
|
| 33.
|
O'Brien, T. C.,
P. Albrecht,
H. P. Schumacher, and N. M. Tauraso.
1971.
Isolation of foamy virus types 1 and 2 from primary rhesus monkey brain cultures.
Proc. Soc. Exp. Biol. Med.
137:1318-1323[Medline].
|
| 34.
|
O'Brien, T. C.,
P. Albrecht,
J. Hannah,
N. Tauraso,
B. Robbins, and R. Trimmer.
1972.
Foamy virus serotypes 1 and 2 in rhesus monkey tissues.
Arch. Gesamte Virusforsch.
38:216-224[Medline].
|
| 35.
|
Renne, R.,
E. Friedl,
M. Schweizer,
U. Fleps,
R. Turek, and D. Neumann-Haefelin.
1992.
Genomic organization and expression of simian foamy virus type 3 (SFV-3).
Virology
186:597-608[Medline].
|
| 36.
|
Rhodes-Feuillette, A.,
F. Saal,
J. Lasneret,
P. Dubouch, and J. Peries.
1979.
Isolation and characterization of a new simian foamy virus serotype from lymphocytes of a Papio cynocephalus baboon.
J. Med. Primatol.
8:308-320[Medline].
|
| 37.
|
Schliephake, A. W., and A. Rethwilm.
1994.
Nuclear localization of foamy virus Gag precursor protein.
J. Virol.
68:4946-4954[Abstract/Free Full Text].
|
| 38.
|
Schnitzer, T. J.
1979.
Phenotypic mixing between two primate oncoviruses.
J. Gen. Virol.
42:199-206[Abstract/Free Full Text].
|
| 39.
|
Schweizer, M.,
U. Fleps,
A. Jackle,
R. Renne,
R. Turek, and D. Neumann-Haefelin.
1993.
Simian foamy virus type 3 (SFV-3) in latently infected Vero cells: reactivation by demethylation of proviral DNA.
Virology
192:663-666[Medline].
|
| 40.
|
Schweizer, M.,
R. Turek,
H. Hahn,
A. Schliephake,
K.-O. Netzer,
G. Eder,
M. Reinhardt,
A. Rethwilm, and D. Neumann-Haefelin.
1995.
Markers of foamy virus infections in monkeys, apes, and accidently infected humans: appropriate testing fails to confirm suspected foamy virus prevalence in humans.
AIDS Res. Hum. Retroviruses
11:161-170[Medline].
|
| 41.
|
Schweizer, M.,
V. Falcone,
J. Gange,
R. Turek, and D. Neumann-Haefelin.
1997.
Simian foamy virus isolated from an accidentally infected human individual.
J. Virol.
71:4821-4824[Abstract].
|
| 42.
| Shahabuddin, M., et al. Unpublished data.
|
| 43.
|
Swack, N. S., and G. D. Hsiung.
1975.
Pathogenesis of simian foamy virus infection in natural and experimental hosts.
Infect. Immun.
12:470-474[Abstract/Free Full Text].
|
| 44.
|
Teich, N.,
J. Wyke, and P. Kaplan.
1985.
Pathogenesis of retrovirus-induced disease, p. 187-248.
In
R. Weiss, N. Teich, H. Varmus, and J. Coffin (ed.), RNA tumor viruses: molecular biology of tumor viruses, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 45.
|
von Laer, D.,
D. Neumann-Haefelin,
J. L. Heeney, and M. Schweizer.
1996.
Lymphocytes are the major reservoir for foamy viruses in peripheral blood.
Virology
221:240-244[Medline].
|
| 46.
|
Voss, G.,
S. Nick,
C. Stahl-Hennig,
K. Ritter, and G. Hunsmann.
1992.
Generation of macaque B lymphoblastoid cell lines with simian Epstein-Barr-like viruses: transformation procedure, characterization of cell lines and occurrence of simian foamy virus.
J. Virol. Methods
39:185-195[Medline].
|
| 47.
|
Weiss, R. A.
1988.
A virus in search of a disease.
Nature (London)
333:497-498[Medline].
|
| 48.
|
Wyand, M. S.,
K. H. Manson,
M. Garcia-Moll,
D. Montefiori, and R. C. Desrosiers.
1996.
Vaccine protection by a triple deletion mutant of simian immunodeficiency virus.
J. Virol.
70:3724-3733[Abstract].
|